The Addition of Recombinant Vaccinia HER2/neu to Oncolytic Vaccinia-GMCSF Given into the Tumor Microenvironment Overcomes MDSC-Mediated Immune Escape and Systemic Anergy

Effective immunotherapeutic strategies require the ability to generate a systemic antigen-specific response capable of impacting both primary and metastatic disease. We have built on our oncolytic vaccinia GM-CSF strategy by adding recombinant tumor antigen to increase the response in the tumor micr...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Christiaan R., Monken, Claude E., Lattime, Edmund C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397129/
https://www.ncbi.nlm.nih.gov/pubmed/25633483
http://dx.doi.org/10.1038/cgt.2015.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397129/
https://www.ncbi.nlm.nih.gov/pubmed/25633483
http://dx.doi.org/10.1038/cgt.2015.2

Ejemplares similares